MicroRNA-466 with tumor markers for cervical cancer screening.

Li-Li Zhou,Jiao-Mei Gong,Ping Sun,Jia-He Sheng,Yong Shen

doi:10.18632/oncotarget.19992

Li-Li Zhou, Jiao-Mei Gong + Show 3 more

Open Access

https://doi.org/10.18632/oncotarget.19992

Copy DOI

Abstract

Cervical cancer is the second most common cancer in women in the world. In this study, we explore tumor markers and microRNA-466 combination for cervical cancer screening. Tumor markers were measured by the methods of electro-chemiluminescent immunoassay and enzyme immunoassay. The microRNA-466 was performed by quantitative real-time polymerase chain reaction. Among normal group, hyperplasia group and cancer group, the CEA expression levels were 2.26 ng/ml, 3.85 ng/ml and 16.08 ng/ml, respectively. While the CA125 expression levels were 13.61 u/ml, 27.32 u/ml and 44.93 u/ml, respectively. The SCCA expression levels were 13.61 ng/ml, 27.32 ng/ml and 44.93 ng/ml, respectively. The expression levels of tumor markers were all gradually increased with the development of cervical lesions. The expression levels of microRNA-466 in cervical cancers (0.62) were greater than that in normal (0.076) and hyperplasia (0.24). The expression of microRNA-466 was correlated with lymphnode metastasis (P=0.000). There is a lower overall survival rate of patient with large tumor or lymphnode metastasis. Thus, the combination of tumor markers and microRNA-466 can be useful for early detection of cervical cancer and indicators for advanced stage and prognosis of the disease.

Highlights

Cervical cancer is the second most frequent cancer in women and the most common gynecological cancer [1]
Squamous cell www.impactjournals.com/oncotarget carcinoma antigen (SCCA) is separated from a squamous cell carcinoma (SCC) of the uterine cervix [13]. These results suggest that cervical adenocarcinoma may excrete elevated levels of carcinoembryonic antigen (CEA) and/or SCCA in cervical cancer instead of cancer antigen 125 (CA125)
It was shown that the expression levels of CEA were gradually built up over the development of cervical lesions

Summary

Introduction

Cervical cancer is the second most frequent cancer in women and the most common gynecological cancer [1]. 85% of new cases occur in developing countries where the survival rates are substantially lower as a result of a presentation at relatively advanced stages [3] This condition affects severely the health and lives with the women [4]. MicroRNAs (miRNAs), small non-coding short RNAs of 18-25 nucleotides in length, generally act as negative regulators of gene expression at the posttranscriptional level through mRNA degradation or translation repression [5, 6]. These molecules, as key regulators of cellular growth and differentiation, play an important role in many biological processes [7, 8]. The expression levels of MicroRNA-466 in cervical cancer tissue have been reported in our previous study [11]

Methods

Results

Conclusion